These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3662477)

  • 1. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
    Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
    Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
    Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
    Kende M
    J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator.
    Peters CJ; Reynolds JA; Slone TW; Jones DE; Stephen EL
    Antiviral Res; 1986 Aug; 6(5):285-97. PubMed ID: 2429616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of interferon responses to poly ICLC in males and females.
    Bever CT; McFarlin DE; Levy HB
    J Interferon Res; 1985; 5(3):423-8. PubMed ID: 2414373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortisol induction by poly ICLC: implications for clinical trials of interferon.
    Bever CT; McFarland HF; Levy HB; McFarlin DE
    Ann Neurol; 1988 Feb; 23(2):196-9. PubMed ID: 2454067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
    Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
    Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.
    Crane LR; Levy HB; Lerner AM
    Antimicrob Agents Chemother; 1982 Mar; 21(3):481-5. PubMed ID: 7049075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol
    Kumaki Y; Salazar AM; Wandersee MK; Barnard DL
    Antiviral Res; 2017 Mar; 139():1-12. PubMed ID: 27956136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
    Pessina GP; Muscettola M; Paulesu L; Bocci V
    J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.
    Wong JP; Saravolac EG; Sabuda D; Levy HB; Kende M
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2574-6. PubMed ID: 8585749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of mouse tumor to interferon inducer and radiation.
    Lvovsky EA; Mossman KL; Levy HB; Dritschilo A
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1721-5. PubMed ID: 4030439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
    Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
    Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
    Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
    Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC).
    Leventhal BG; Kashima H; Levine AS; Levy HB
    J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106
    [No Abstract]   [Full Text] [Related]  

  • 18. Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
    Awasthi A; Mehrotra S; Bhakuni V; Dutta GP; Levy HB; Maheshwari RK
    J Interferon Cytokine Res; 1997 Jul; 17(7):419-23. PubMed ID: 9243375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice.
    Kende M; Alving CR; Rill WL; Swartz GM; Canonico PG
    Antimicrob Agents Chemother; 1985 Jun; 27(6):903-7. PubMed ID: 4026264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
    Puri SK; Dutta GP; Levy HB; Maheshwari RK
    J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.